Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of empagliflozin on the renin-angiotensin system in chronic kidney disease
2016-002935-14Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Primary endpoint: Change in angiotensin 1-7. Started Oct 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-002935-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002935-14.